Well Referenced

Tag: cancer progression

Acute and Chronic Cadmium Exposure Promotes E-Cadherin Degradation in MCF7 Breast Cancer Cells

This study investigates the effects of both acute and chronic cadmium (Cd) exposure on E-cadherin degradation in MCF7 breast cancer cells. The researchers found that Cd exposure leads to the degradation of E-cadherin via the ubiquitination pathway, resulting in reduced E-cadherin/β-catenin complexes and increased nuclear translocation of β-catenin. This translocation

Read More »
June 26, 2025 No Comments

Chronic stress-induced immune dysregulation in cancer: implications for initiation, progression, metastasis, and treatment

This comprehensive review explores how chronic psychological stress disrupts immune regulation, thereby influencing cancer initiation, progression, metastasis, and therapeutic resistance. Chronic stress activates the hypothalamic-pituitary-adrenal (HPA) axis and sympathetic nervous system, leading to elevated levels of glucocorticoids and catecholamines. These hormonal changes impair immune surveillance by promoting the expansion of

Read More »
June 26, 2025 No Comments

Role of glutathione in cancer progression and chemoresistance

This review examines the dual role of glutathione (GSH) in cancer biology, emphasizing its involvement in both cancer progression and chemoresistance. While GSH deficiency increases oxidative stress and may promote carcinogenesis, elevated GSH levels provide antioxidant protection to tumor cells, helping them resist chemotherapy-induced damage. The review highlights the complex

Read More »
June 26, 2025 No Comments

Does testosterone have a role in erectile function?

This article explores the use of testosterone replacement therapy (TRT) in men with prostate cancer, emphasizing the risks and benefits of its use. It finds that TRT can lead to increased PSA levels, potentially signaling cancer progression. The study highlights the importance of careful monitoring during treatment, as elevated PSA

Read More »
June 26, 2025 No Comments

Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy

This observational study evaluated the safety of testosterone replacement therapy (TRT) in 31 men with symptomatic hypogonadism after undergoing brachytherapy for early-stage prostate cancer. Over a median follow-up of 5 years post-brachytherapy, TRT increased median testosterone levels from 188 ng/dL to 498 ng/dL without causing biochemical recurrence. No patients experienced

Read More »
June 26, 2025 No Comments